- Home
- AGMH vs ATHA Comparison
AGMH vs ATHA Comparison
Compare AGMH & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- ATHA
- Stock Information
- Founded
- AGMH 2015
- ATHA 2011
- Country
- AGMH Hong Kong
- ATHA United States
- Employees
- AGMH N/A
- ATHA N/A
- Industry
- AGMH EDP Services
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- AGMH Technology
- ATHA Health Care
- Exchange
- AGMH Nasdaq
- ATHA Nasdaq
- Market Cap
- AGMH 18.2M
- ATHA 21.0M
- IPO Year
- AGMH 2018
- ATHA 2020
- Fundamental
- Price
- AGMH $0.69
- ATHA $0.43
- Analyst Decision
- AGMH
- ATHA Buy
- Analyst Count
- AGMH 0
- ATHA 4
- Target Price
- AGMH N/A
- ATHA $11.25
- AVG Volume (30 Days)
- AGMH 47.0K
- ATHA 210.5K
- Earning Date
- AGMH 03-04-2025
- ATHA 03-04-2025
- Dividend Yield
- AGMH N/A
- ATHA N/A
- EPS Growth
- AGMH N/A
- ATHA N/A
- EPS
- AGMH N/A
- ATHA N/A
- Revenue
- AGMH $64,998,081.00
- ATHA N/A
- Revenue This Year
- AGMH N/A
- ATHA N/A
- Revenue Next Year
- AGMH N/A
- ATHA N/A
- P/E Ratio
- AGMH N/A
- ATHA N/A
- Revenue Growth
- AGMH N/A
- ATHA N/A
- 52 Week Low
- AGMH $0.47
- ATHA $0.41
- 52 Week High
- AGMH $2.19
- ATHA $4.21
- Technical
- Relative Strength Index (RSI)
- AGMH 27.43
- ATHA 34.62
- Support Level
- AGMH $0.70
- ATHA $0.42
- Resistance Level
- AGMH $0.87
- ATHA $0.46
- Average True Range (ATR)
- AGMH 0.06
- ATHA 0.04
- MACD
- AGMH 0.01
- ATHA -0.00
- Stochastic Oscillator
- AGMH 0.00
- ATHA 10.85
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.